% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Apr 23, 2013 7:03 AM Flag


    Abstract #11095
    The source for this was the IV board, not ASCO, I have not confirmed this, just pasted from IV.

    MRI apparent diffusion coefficient in a murine orthotopic glioblastoma model as a clinically translatable early readout of efficacy for AMG 595, an antibody drug conjugate targeting EGFRvIII.
    Brittany Yerby, BA

    Abstract #2071
    An EGFRvIII-specific IHC IUO test for patient selection in AMG 595 phase I trial.
    Michael A. Damore, PhD

    Abstract #2573
    A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.
    Carla Kurkjian, MD

    Abstract #644
    Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC).
    Bei Wang

2.78-0.03(-1.07%)Jul 26 4:00 PMEDT